What are the characteristics of ABIVAX stock?

ABIVAX is a company operating in the Santé · Biotechnologies · Pharmacie sector. The stock is listed on Euronext Paris under ISIN FR0012333284.

What is the recent price evolution of ABIVAX stock?

Since last close: 5.49 %. Over one week: 9.26 %. Over one year: 1527 %.

Abivax Buys Back Royalty Certificates and Raises $45 Million in ADS

Abivax has announced the buyback of its Royalty Certificates. The company is also issuing $45 million (€38.5 million) in American Depositary Shares.

Published on May 05, 2026 at 10:49

ABIVAX

105.60 € +5.49 %

Buyback of Royalty Certificates and Fundraising

Abivax is proceeding with the buyback of its Royalty Certificates. Concurrently, the company is launching an issuance of American Depositary Shares (ADS) amounting to $45 million, equivalent to €38.5 million.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Santé

🗞️ DBV Technologies Stock Rises to €3.43 Despite Lowered Price Target 🗞️ Emeis Stock Rises 2.7% to €14.81 Ahead of Q1 2026 Revenue Announcement 🗞️ Clariane's Stock Surpasses €4, Eyes Resistance at €4.10 🗞️ Nanobiotix Shares Surge Forward Following FDA Green Light on NANORAY-312

Context

Period

Period: 3T 2025

Guidance from the release

Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.

Risks mentioned

Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)

Opportunities identified

Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Buyback of Royalty Certificates and Fundraising

Context

Also read